Why Amarin Investors Have Their Eyes on Nov. 14

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 14, 2019 at 12:02 AM.

  1. #1 cafead, Oct 14, 2019 at 12:02 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,013
    Likes Received:
    3
    via So much for an accelerated approval timeline. Amarin (NASDAQ: AMRN) had once expected that the Food and Drug Administration would weigh in on a supplemental new drug application (sNDA) for Vascepa by the end of September. The drug earned priority review from regulators, who otherwise wouldn't have made a decision on the application until January 2020. But the accelerated timeline never materialized.

    article source
     
    Quote

Reply to Thread